Master protocol trials in oncology: Review and new trial designs

In oncology, next generation sequencing and comprehensive genomic profiling have enabled the detailed classification of tumors using molecular biology. However, it is unrealistic to conduct phase I–III trials according to each sub-population based on patient molecular subtypes. Common protocols that...

Full description

Bibliographic Details
Main Authors: Akihiro Hirakawa, Junichi Asano, Hiroyuki Sato, Satoshi Teramukai
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865418300565
id doaj-1fb9d0f5d7ad402d97d9ae65a4070044
record_format Article
spelling doaj-1fb9d0f5d7ad402d97d9ae65a40700442020-11-25T02:32:42ZengElsevierContemporary Clinical Trials Communications2451-86542018-12-011218Master protocol trials in oncology: Review and new trial designsAkihiro Hirakawa0Junichi Asano1Hiroyuki Sato2Satoshi Teramukai3Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8654, Japan; Corresponding author. Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan.Biostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, 100-0013, JapanBiostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, 100-0013, JapanDepartment of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, JapanIn oncology, next generation sequencing and comprehensive genomic profiling have enabled the detailed classification of tumors using molecular biology. However, it is unrealistic to conduct phase I–III trials according to each sub-population based on patient molecular subtypes. Common protocols that assess the combination of several molecular markers and their targeted therapies by means of multiple sub-studies are required. These protocols are called “master protocols,” and are drawing attention as a next-generation clinical trial design. Recently, several reviews of clinical trials based on the master protocol design have been published, but their definitions of these such trials, including basket, umbrella, and platform trials, were not consistent. Concurrently, the acceleration of the development of new statistical designs for master protocol trials has been underway. This article provides an overview of recent reviews for master protocols, including their statistical design methodologies in Oncology. We also introduce several examples of previous and on-going master protocol trials along with their classifications by some recent studies. Keywords: Master protocol, Basket, Umbrella, Platform, Bayesian adaptive methodhttp://www.sciencedirect.com/science/article/pii/S2451865418300565
collection DOAJ
language English
format Article
sources DOAJ
author Akihiro Hirakawa
Junichi Asano
Hiroyuki Sato
Satoshi Teramukai
spellingShingle Akihiro Hirakawa
Junichi Asano
Hiroyuki Sato
Satoshi Teramukai
Master protocol trials in oncology: Review and new trial designs
Contemporary Clinical Trials Communications
author_facet Akihiro Hirakawa
Junichi Asano
Hiroyuki Sato
Satoshi Teramukai
author_sort Akihiro Hirakawa
title Master protocol trials in oncology: Review and new trial designs
title_short Master protocol trials in oncology: Review and new trial designs
title_full Master protocol trials in oncology: Review and new trial designs
title_fullStr Master protocol trials in oncology: Review and new trial designs
title_full_unstemmed Master protocol trials in oncology: Review and new trial designs
title_sort master protocol trials in oncology: review and new trial designs
publisher Elsevier
series Contemporary Clinical Trials Communications
issn 2451-8654
publishDate 2018-12-01
description In oncology, next generation sequencing and comprehensive genomic profiling have enabled the detailed classification of tumors using molecular biology. However, it is unrealistic to conduct phase I–III trials according to each sub-population based on patient molecular subtypes. Common protocols that assess the combination of several molecular markers and their targeted therapies by means of multiple sub-studies are required. These protocols are called “master protocols,” and are drawing attention as a next-generation clinical trial design. Recently, several reviews of clinical trials based on the master protocol design have been published, but their definitions of these such trials, including basket, umbrella, and platform trials, were not consistent. Concurrently, the acceleration of the development of new statistical designs for master protocol trials has been underway. This article provides an overview of recent reviews for master protocols, including their statistical design methodologies in Oncology. We also introduce several examples of previous and on-going master protocol trials along with their classifications by some recent studies. Keywords: Master protocol, Basket, Umbrella, Platform, Bayesian adaptive method
url http://www.sciencedirect.com/science/article/pii/S2451865418300565
work_keys_str_mv AT akihirohirakawa masterprotocoltrialsinoncologyreviewandnewtrialdesigns
AT junichiasano masterprotocoltrialsinoncologyreviewandnewtrialdesigns
AT hiroyukisato masterprotocoltrialsinoncologyreviewandnewtrialdesigns
AT satoshiteramukai masterprotocoltrialsinoncologyreviewandnewtrialdesigns
_version_ 1724818323908067328